Cell publication: Precision Microbiome Profiling (PMP™) demonstrates it diagnostic potential in groundbreaking work conducted at Gustave Roussy Cancer Institute
TOPOSCORE, a bacterial signature for reliably predicting response to immune checkpoint inhibitor treatment in cancer patients, has been successfully validated on PMP™, demonstrating the clinical utility of Bio-Me’s proprietary platform.
17 September, 2024Press Release: Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood
Dr. Arne Materna has been appointed Co-CEO as of July 1st, 2024 to strengthen the company’s capitalization and continued commercial growth. Read More
12 September, 2024Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk
The PREVALUNG EU program aims to implement cancer risk stratification tools and personalized interventions to intercept lung cancer in cardiovascular patients. Bio-Me’s Precision Microbiome Profiling (PMP™) was chosen for high-throughput gut microbiome profiling.
07 September, 2023Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication
PMP™ was used in a recent study to identify gut microbial species that are directly associated with appendicular lean mass and bone mineral density. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™.
27 April, 2023Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD
PMP™ was used in a recent study to explore the gut microbiome of children with inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children. Diagnostic, Phenotype and Prognostic Indexes were constructed based on PMP™ data with very good discriminating properties.
05 August, 2022Bio-Me strengthens its international commercial team with key hire
Bio-Me has employed Dr. Anne-Grethe Reichelt as part of the company’s plan to widen commercial adoption of their existing product portfolio and launch new products under development. Read More
04 July, 2022Bio-Me Joins Medicen Working Group
Bio-Me has joined the Medicen Working Group, an international initiative focusing on drug-microbiome interactions. The aim of the group is to accelerate the microbiome integration in the drug discovery and development process. Read More
01 July, 2022Bio-Me´s technology demonstrates its usefulness in metabolic syndrome research in a Lancet publication
PMP™ has shown its applicability in obesity research in a study published in The Lancet. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™. Read More
10 June, 2022Bio-Me Joins Microbiome Therapeutics Innovation Group
Bio-Me has joined MTIG. Group members work together to accelerate microbiome-based drug development and expand availability of approved microbiome therapies to patients. Read More
26 April, 2022Dr. Warren Flood steps up as CEO of Bio-Me
Bio-Me has appointed a new CEO as part of the company’s strategic plan to be positioned as a leader in the microbiome-based Precision Medicine space. Read More
02 March, 2022Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP™ technology can support researchers and industry
Our COO, Warren Flood, will be participating in a webinar together with Thermo Fisher Scientific on September 22nd with a focus on our PMP™ technology and its applicability. Read More
08 September, 2021Bio-Me restructures board with Gilhuus-Moe becoming Executive Chair
Bio-Me has announced a major board restructuring that will support the Company during its new phase of development. Read More
02 July, 2021Bio-Me represented with two presentations at the 6th Microbiome Movement – Drug Development Summit 2021
Bio-Me has been invited to present at the upcoming Microbiome Movement - Drug Development Summit. Read More
29 June, 2021Bio-Me granted public funding to become part of ground-breaking research on long-term effects of COVID-19 in adolescents and young adults
Bio-Me and Akershus University Hospital aim to explore gut microbiome profiles linked to long-term effects of COVID-19. Read More
28 June, 2021Bio-Me secures NOK 10 mill in financing
Bio-Me today announced that it has successfully raised NOK 10 mill in a fully subscribed funding round. Both existing and new investors participated in the financing round, with new investors contributing to the majority of the capital. Read More
10 June, 2021Bio-Me and Siolta Therapeutics to collaborate on developing microbiome-based pediatric allergy and asthma test
Bio-Me and Siolta Therapeutics aim to develop and market predictive test for infants.
Read More23 November, 2020Bio-Me strengthens Board of Directors to focus on clinical development of microbiome profiling tests
Bio-Me today announced that a new Board of Directors has been approved by the general assembly.
Read More13 July, 2020Bio-Me strengthens their team with the hire of a Chief Clinical Officer
Runar Vige has taken on the role of Chief Clinical Officer. Runar brings more than 20 years of broad interdisciplinary experience working with companies like Pfizer, Pronova BioPharma, and BASF.
Read More05 June, 2020Bio-Me receives 2 million Euro in public funding
Bio-Me has received 2 million Euro in grants and public support from The Research Council of Norway to develop a companion diagnostic test for immune checkpoint inhibitor cancer treatments.
Read More23 April, 2020Bio-Me part of unique Nordic IBD initiative
Bio-Me is one of the participants in a new Nordic project that will develop personalized treatment for IBD patients.
Read More12 August, 2019Official Opening of Service Laboratory
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory.
Read More14 June, 2019Bio-Me deal with top 10 Consumer Company
Bio-Me has entered into an agreement with one of the top ten consumer healthcare companies worldwide.
Read More19 February, 2019Bio-Me at 4th National Microbiota Conference
Dr. Morten Isaksen, CEO of Bio-Me, has been invited to present Bio-Me and its contribution to use of information from the gut microbiome in clinical settings.
Read More19 February, 2019Dr. Morten Isaksen on LØRN podcast
Morten Isaksen, CEO of Bio-Me, is featured on LØRN, leading Norwegian technology blog and podcast service.
Read More07 December, 2018Bio-Me to receive Aleap Pre-Seed Fund
Bio-Me is pleased to announce that it has been selected as the recipient of Aleap Pre-Seed Fund.
Read More20 November, 2018Bio-Me takes part in Katapult Accelerator
After a globally competitive process spanning two months, Bio-Me was selected as one of twelve companies to be part of Katapult Accelerator (KA) Batch 3. Read More
28 August, 2018Bio-Me one of 25 most innovative companies
INNOMAG, the leading innovation magazine in Norway, has selected Bio-Me as one of the 25 most innovative new companies in Norway in 2018. Read More
26 June, 2018Dr. Morten L. Isaksen speaks at conference
The conference brings together leaders and executives from the pharmaceutical, biotech, academic, and government communities. Read More
09 April, 2018Norwegian Prime Minister visits Bio-Me
The Prime Minister was very attentive and eager to learn how GutChek(TM) from Bio-Me, combined with information and samples from HUNT can provide better health treatment and preventative measures. Read More
21 March, 2018Bio-Me at Microbiome R&D Business Forum
Bio-Me will be presenting new results from the development of its proprietary GutCheck(TM) gut microbiome analysis platform Read More
12 March, 2018Dr. Isaksen speaks at Big Data Conference
On Wednesday 14th February, Tekna, the main national engineering society in Norway, invited its members to an evening regarding the use of Big Data in the Norwegian health innovation system. Read More
14 February, 2018Bio-Me & NTNU (HUNT4) sign agreement
In a milestone agreement, Bio-Me and NTNU have signed a Collaboration Agreement, giving Bio-Me access to analyze the approximately 30,000 fecal samples that will be collected as part of the ongoing HUNT 4 study. Read More
03 October, 2017Bio-Me first tenant at OsloTech’s ShareLab
Bio-Me became the first tenant at ShareLab, the premium laboratory hotel offered by OsloTech as part of Oslo Research Park, close to the University of Oslo and Oslo University Hospital. Read More
02 October, 2017Bio-Me attends RESI Boston conference
As part of their future plans of expansion into the North American market, Bio-Me will be attending the RESI Boston conference on Monday 25th September 2017. Read More
27 September, 2017Bio-Me signs a Joint Venture with MiNiSV
In a historic moment, Bio-Me signed an agreement for setting up a Joint Venture and License Agreement with MiNiSV in Nanjing, China. Read More
16 January, 2018Bio-Me present at Microbiome Invest Forum
At the recent Microbiome Invest Forum in London, organized by Kisaco Research, Bio-Me was invited to present data from their development of GutCheck(TM), the next generation gut microbiome analysis. Read More
31 May, 2017Bio-Me presentation available online
Morten L. Isaksen, CEO of Bio-Me, was invited to give a presentation on the future of gut microbiome analysis at the recent 4th Microbiome R&D and Business Collaboration Forum in Amsterdam 3 - 4 April 2017. Read More
24 May, 2017Collaboration agreement with the University of Oslo
Bio-Me and the University of Oslo, Department of Biosciences, Centre for Ecological and Evolutionary Synthesis (CEES) have entered into a collaboration agreement Read More
22 December, 2016Bio-Me awarded grant from RCN
Bio-Me AS has been awarded a grant under The Programme for Regional R&D and Innovation (VRI) from the Research Council of Norway (RCN) Read More
05 December, 2016Bio-Me AS presents at DNB NXT Oslo
Bio-Me AS has been selected to present at the Norwegian Investment Forum 2016, organized in partnership with DNB at DNB NXT, as part of Oslo Innovation Week. Read More
14 October, 2016HRH the Crown Prince opens Aleap
Wednesday 12th October was the official opening of Aleap - the new Health Incubator located at the Oslo Science Park, where Bio-Me AS is located. Read More
13 October, 2016Norwegian King and Queen watch as Bio-Me presents
As one of only four selected companies, Bio-Me AS will present to investors and angel investors in Helsinki, Finland. Read More
19 August, 2016Bio-Me AS presents at SeedForum Stockholm
Bio-Me AS will present its business case at the SeedForums investor event hosted by Carnegie Investment Bank in Stockholm 9th September 2016. Read More
21 June, 2016
